AGEs Cancer Research Results

AGEs, Advanced Glycation End Products: Click to Expand ⟱
Source:
Type:
Advanced Glycation End Products (AGEs) are highly reactive compounds formed when proteins or lipids become non-enzymatically glycated after exposure to sugars. AGEs accumulate with age and are implicated in various chronic diseases—including Alzheimer’s disease (AD).
-AGEs bind to Aβ peptides, increasing aggregation and plaque stability.
-AGEs activate kinases like GSK-3β and p38 MAPK, promoting tau phosphorylation.
-Human brains with AD show increased AGE-modified proteins and elevated RAGE expression.
-Blocking RAGE or reducing AGEs slows cognitive decline and pathology in mice.

Strategies to Reduce AGE Burden
-Low-AGE cooking (steaming, boiling), Mediterranean diet
- reduce processed meats, sugary baked goods, and fried foods.
Scientific Papers found: Click to Expand⟱
6010- CGA,    The Biological Activity Mechanism of Chlorogenic Acid and Its Applications in Food Industry: A Review
- Review, Nor, NA
*antiOx↑, *hepatoP↑, *RenoP↑, AntiTum↑, *glucose↝, *Inflam↓, *neuroP↑, *ROS↓, *Keap1↓, *NRF2↑, *SOD↑, *Catalase↑, *GPx↑, *GSH↑, *MDA↓, *p‑ERK↑, *GRP78/BiP↑, *CHOP↑, *GRP94↑, *Casp3↓, *Casp9↓, *HGF/c-Met↑, *TNF-α↓, *TLR4↓, *MAPK↓, *IL1β↓, *iNOS↓, TCA↓, Glycolysis↓, Bcl-2↓, BAX↑, MAPK↑, JNK↑, CSCs↓, Nanog↓, SOX2↓, CD44↓, OCT4↓, P53↑, P21↑, *SOD1↑, *AGEs↓, *GLUT2↑, *HDL↑, *Fas↓, *HMG-CoA↓, *NF-kB↓, *HO-1↓, *COX2↓, *TLR4↓, *BioAv↑, *BioAv↝, TumCP↓, TumCMig↓, TumCI↓,
5998- Chit,    Trial: Chitosan can help reduce AGE levels in patients with prostate cancer.
- Trial, Pca, NA
AGEs↓, Wound Healing↑, Obesity↓,
4529- MAG,    Effectiveness of Magnolol, a Lignan from Magnolia Bark, in Diabetes, Its Complications and Comorbidities—A Review
- Review, Diabetic, NA
*AntiDiabetic↑, *glucose↓, *SOD↑, *Catalase↑, *ROS↓, *MDA↓, *GPx↑, *CYP2E1↓, *AGEs↓, *IL10↑, *neuroP↑, *GutMicro↑,
5795- MET,    Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
- Review, AD, NA - Review, Park, NA - Review, Diabetic, NA
*AntiDiabetic↑, *AMPK↑, *glyC↓, *ROS↓, *cardioP↑, *neuroP↑, *Half-Life↝, *toxicity↝, *BioAv↑, *glucose↓, *AGEs↓, AntiCan↑, Risk↓, TumCP↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, pRB↓, p27↓, mTOR↓, Casp↑, ROS↑, MMP↓, ChemoSen↑, *hepatoP↑, *CRM↑, *Insulin↓,
4312- VitB1/Thiamine,    Pharmacological thiamine levels as a therapeutic approach in Alzheimer's disease
- Review, AD, NA
*eff↑, *cognitive↑, *memory↑, *GlucoseCon↑, *Aβ↓, *Inflam↓, *antiOx↑, *p‑tau↓, *AGEs↓, *Dose↝,
4311- VitB1/Thiamine,    Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathy
- in-vivo, AD, NA
*Aβ↓, *p‑tau↓, *ROS↓, *cognitive↑, *OS↑, *Mood↑, *neuroP↑, *Inflam↓, *NRF2↑, *PGC-1α↑, *AGEs↓, *4-HNE↓, *NQO1↑, *COX2↓, *TNF-α↓, *IL1β↓, *NF-kB↓, *GSK‐3β↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   TCA↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 1,   JNK↑, 1,   MAPK↑, 1,   p27↓, 1,  

Transcription & Epigenetics ⓘ

pRB↓, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CSCs↓, 1,   mTOR↓, 1,   Nanog↓, 1,   OCT4↓, 1,   SOX2↓, 1,  

Migration ⓘ

TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 2,  

Protein Aggregation ⓘ

AGEs↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   AntiTum↑, 1,   Obesity↓, 1,   Risk↓, 1,   Wound Healing↑, 1,  
Total Targets: 32

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

4-HNE↓, 1,   antiOx↑, 2,   Catalase↑, 2,   CYP2E1↓, 1,   GPx↑, 2,   GSH↑, 1,   HDL↑, 1,   HO-1↓, 1,   Keap1↓, 1,   MDA↓, 2,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 4,   SOD↑, 2,   SOD1↑, 1,  

Mitochondria & Bioenergetics ⓘ

Insulin↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 1,   CRM↑, 1,   glucose↓, 2,   glucose↝, 1,   GlucoseCon↑, 1,   GLUT2↑, 1,   glyC↓, 1,   HMG-CoA↓, 1,  

Cell Death ⓘ

Casp3↓, 1,   Casp9↓, 1,   Fas↓, 1,   HGF/c-Met↑, 1,   iNOS↓, 1,   MAPK↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   GRP78/BiP↑, 1,   GRP94↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↑, 1,   GSK‐3β↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL10↑, 1,   IL1β↓, 2,   Inflam↓, 3,   NF-kB↓, 2,   TLR4↓, 2,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

p‑tau↓, 2,  

Protein Aggregation ⓘ

AGEs↓, 5,   Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 2,   BioAv↝, 1,   Dose↝, 1,   eff↑, 1,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

GutMicro↑, 1,  

Functional Outcomes ⓘ

AntiDiabetic↑, 2,   cardioP↑, 1,   cognitive↑, 2,   hepatoP↑, 2,   memory↑, 1,   Mood↑, 1,   neuroP↑, 4,   OS↑, 1,   RenoP↑, 1,   toxicity↝, 1,  
Total Targets: 62

Scientific Paper Hit Count for: AGEs, Advanced Glycation End Products
2 Vitamin B1/Thiamine
1 Chlorogenic acid
1 chitosan
1 Magnolol
1 Metformin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1375  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page